“When you are seeing great results in your research lab, you think that everything has been done. But then when you try to humanise your drug, a new adventure starts, because the CMC process is very difficult. In my opinion,
“Gene editing and cell therapy, they’re going to be entrenched modalities, much like small molecules and antibodies are today, that will fundamentally reshape healthcare.” says Devyn Smith. Devyn Smith, CEO of Arbor Biotechnologies and Chairman of the Alliance for Regenerative
“We hide behind the hubris of science, but we still have a lot of operational challenges to really impact the lives of our patients,” warns Sanjay Srivastava, Managing Director of Accenture’s Centre of Excellence for Cell & Gene Therapy. This
Pluri Inc., a biotechnology firm based in Haifa, Israel, recently announced the launch of two new business verticals. These are PluriAgtech and PluriCDMO, aimed at leveraging its cell-based technology in agriculture and providing contract development and manufacturing services, respectively. The company’s
Alan Runcus, UK Sales Manager, explains World Couriers personalised, intelligent supply chain
Rathish Ravindrakumar explains the services the CDMO offers and the importance of sustainability to the pharma supply chain.
